> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Moderna Flu/Covid Vaccine Beats Comparators: Study
- URL: https://www.fdaweb.com/moderna-flu-covid-vaccine-beats-comparators-study/
- Published: 2025-05-07T12:00:00.000Z
- Updated: 2026-09-14T15:11:16.000Z
- Author: David McFarland
- Tags: Biologics, #legacy-id-D5159134

Moderna Phase 3 research found that its investigational mRNA-1083 combination flu and Covid-19 vaccine demonstrated noninferiority and induced higher immune responses than the recommended standard of care flu and Covid-19 vaccines in adults aged 50 and older. The company [reported](https://jamanetwork.com/journals/jama/fullarticle/2833668?guestAccessKey=143c6ea1-0112-4ea2-8e85-b19e45dd9773&utm%5Fsource=for%5Fthe%5Fmedia&utm%5Fmedium=referral&utm%5Fcampaign=ftm%5Flinks&utm%5Fcontent=tfl&utm%5Fterm=050725) its research in the *Journal of the American Medical Association*.

The report says 8,015 participants were enrolled and vaccinated for the trial. The mRNA-1083 vaccine “was demonstrated to be at least as immunogenic as recommended standard of care vaccines against both seasonal influenza and Covid-19 and well tolerated in adults 50 years and older,” the study says.

The article cites advantages for the mRNA platform, including avoidance of egg adaptation-related changes and the breadth of immunity and T-cell responses for the influenza component. It also notes that the rapid production and flexibility for updates to vaccine composition can ensure close matching to circulating influenza and SARS-CoV-2 virus strains. It says the platform can quickly adapt to allow for timely and effective public health responses, especially in the face of emerging variants and strains.